S0360090
(RS)-Selegilin -hydrochlorid
European Pharmacopoeia (EP) Reference Standard
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C13H17N · HCl
CAS-Nummer:
Molekulargewicht:
223.74
UNSPSC-Code:
41116107
NACRES:
NA.24
Empfohlene Produkte
Qualität
pharmaceutical primary standard
API-Familie
selegiline
Hersteller/Markenname
EDQM
Anwendung(en)
pharmaceutical (small molecule)
Format
neat
Lagertemp.
2-8°C
SMILES String
Cl.N(C(Cc1ccccc1)C)(CC#C)C
InChI
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H
InChIKey
IYETZZCWLLUHIJ-UHFFFAOYSA-N
Allgemeine Beschreibung
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
(RS)-Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Verpackung
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Sonstige Hinweise
Sales restrictions may apply.
Ähnliches Produkt
Produkt-Nr.
Beschreibung
Preisangaben
Hier finden Sie alle aktuellen Versionen:
Analysenzertifikate (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.
Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Tamás Tábi et al.
Expert opinion on drug metabolism & toxicology, 9(5), 629-636 (2013-03-20)
Parkinson's disease affects a growing number of people. Its major treatment, levodopa therapy, however suffers from response fluctuations in the advanced phase of the disease. Adjunctive therapies have thus gained significant importance. The selective monoamine oxidase B inhibitor, selegiline
Johanna E Kowalko et al.
Current biology : CB, 23(19), 1874-1883 (2013-09-17)
Surface populations of Astyanax mexicanus, living in rivers like their common ancestors, school, while several, independently derived cave populations of the same species have lost schooling behavior. We quantify schooling behavior in individual A. mexicanus and identify quantitative trait loci (QTL)
[Primary prevention with enhancer substances for a longer and healthier life].
Ildikó Miklya
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 15(2), 58-59 (2013-07-03)
José A G Agúndez et al.
Expert opinion on drug metabolism & toxicology, 9(7), 859-874 (2013-04-10)
The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers. These biomarkers are then used as surrogate endpoints. This review analyzes potential genetic biomarkers which
Maria J Matos et al.
European journal of medicinal chemistry, 63, 151-161 (2013-03-12)
A series of (coumarin-3-yl)carbamates was synthesized and evaluated in vitro as monoamine oxidase (MAO-A and MAO-B) inhibitors. Most of the new compounds selectively inhibited MAO-B isoenzyme with IC50 values in the micro or nanoMolar ranges. Since these compounds must achieve the
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.